Opendata, web and dolomites

ZENEO

ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ZENEO project word cloud

Explore the words cloud of the ZENEO project. It provides you a very rough idea of what is the project "ZENEO" about.

14    revenues    124m    launch    shock    big    prefilled    right    someone    company    suddenly    allergic    suffer    jobs    sends    patients    threatening    contamination    million    auto    estimate    autoinjectors    solution    innovative    administer    worldwide    situations    guarantee    plan    device    airways    needle    serious    people    adrenaline    risk    crossject    relatives    commercialization    anaphylaxis    roi    counteract    avoiding    fifth    minutes    inject    heart    happen    payback    aged    enter    edge    allergy    guarantees    hospitalizations    close    death    huge    allergies    cutting    filled    seventeen    2021    36    life    syringes    q4    last    136m    injection    young    generate    turnover    food    children    adults    player    causes    zeneo    injector    quick    total    room    properly    anyone    suitable    market    anaphylactic    reg    europeans    prone    emergency    intramuscular    create    performs    free    reactions    discomfort    billion    oxygen    line    reaction    28    profit   

Project "ZENEO" data sheet

The following table provides information about the project.

Coordinator
CROSSJECT 

Organization address
address: 6 RUE PAULINE KERGOMARD ZAC PARC MAZEN SULLY
city: DIJON
postcode: 21000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.crossject.com/en
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CROSSJECT FR (DIJON) coordinator 50˙000.00

Map

 Project objective

Anaphylactic shock is a serious, life-threatening allergic reaction in which the airways suddenly close; if not properly treated it causes death in 20 minutes. Seventeen million Europeans suffer from food allergies, 3.5 million which are children or young adults. Across Europe, food allergy is the leading cause of anaphylaxis in children aged 0-14 years and there is a huge increase in hospitalizations for allergic reactions in children in the last 10 years. Anaphylaxis sends someone to the emergency room every 3 minutes. The only way to counteract an anaphylactic shock is to inject adrenaline to guarantee enough oxygen to the heart. The adrenaline market is estimated to create revenues of €1.2 billion worldwide, and there is only one big player that produce prefilled syringes. Crossject already has the know-how to produce pre-filled needle free autoinjectors, our ZENEO® line. We already have 4 ZENEO® products so we are the right company to enter the adrenaline market with a cutting-edge solution. ZENEO® Adrenaline is an innovative, needle-free, easy-to-use auto-injector suitable for emergency situations, that enables patients and relatives to administer adrenaline. It performs a quick injection (1/10 of a second) avoiding the needle-related discomfort and the risk of contamination, moreover it guarantees intramuscular injection. The end-users of our product are people that are having an anaphylactic shock. People with food allergies are those that will need our device the most as they are more prone to anaphylaxis, however an anaphylactic shock can happen to anyone. We plan to launch ZENEO® Adrenaline on the market in Q4 2021. We will a turnover of €136M and a profit of €124M by the fifth year of commercialization. We expect to achieve the payback between the second and the third year of commercialization and to generate ROI of 3.36 by the fifth year of commercialization. Moreover, we estimate to create a total of 28 new jobs during these 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZENEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZENEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More